clinical trial · NCT05799157
Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts
Verruca VulgarisWartsCommon WartVDMN-21 Patch Low DoseVDMN-21 Patch High DoseVehicle Patch
brief summary
This Phase 2 study has been designed to determine the safety and efficacy of repeated treatment sessions of VDMN-21 patch at two dose strengths as compared to a matched vehicle control patch in subjects with verruca vulgaris
started
Feb 28, 2023
primary completion
Feb 25, 2025
completion
Feb 25, 2025
last updated
May 8, 2025
detailed description
Protocol 250-12951-201 is a planned Phase 2 study entitled "A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of VDMN-21 in Subjects with Verruca Vulgaris". Eligible subjects will be randomized into one of the three treatment groups (high dose, low dose, vehicle).
official title
Protocol 250-1951-201: A Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of VDMN-21 in Subjects With Verruca Vulgaris
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol